Virtus Fund Advisers’s United Therapeutics UTHR Stock Holding History

Virtus Fund Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$1.04M	Buy	+7,018	New	+$892K	0.01%	280
2016 Q1	–	Sell	-139	Closed	-$22K	–	747
2015 Q4	$22K	Sell	139 -22	-14%	-$3.2K	﹤0.01%	507
2015 Q3	$21K	Hold	161	–	–	﹤0.01%	494
2015 Q2	$28K	Sell	161 -791	-83%	-$142K	﹤0.01%	495
2015 Q1	$164K	Sell	952 -94	-9%	-$14.3K	﹤0.01%	422
2014 Q4	$135K	Hold	1,046	–	–	﹤0.01%	489
2014 Q3	$135K	Sell	1,046 -4,533	-81%	-$467K	﹤0.01%	507
2014 Q2	$494K	Buy	+5,579	New	+$537K	﹤0.01%	659

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Virtus Fund Advisers's UTHR Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in United Therapeutics (UTHR) in Q4 2017: 7,018 shares worth $1.04M. The stake represents 0.01% of the portfolio and ranks #280 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in UTHR as recently as Q4 2015.

Virtus Fund Advisers first reported a position in UTHR in Q2 2014 and has held it in 8 quarters since. 400 funds tracked by Wall St. Rank hold UTHR as of Q4 2017.

Virtus Fund Advisers held 7,018 shares of United Therapeutics worth $1.04M as of Q4 2017.
United Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
United Therapeutics made up 0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #280 holding.
Virtus Fund Advisers first reported a position in United Therapeutics in Q2 2014 and has held it in 8 quarters since.
400 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.